Radie Named TransMolecular CEO

Cambridge, MA-based TransMolecular, a developer of cancer drugs based on a molecule derived from scorpion venom, said today it has named Robert Radie as its president and CEO. Before joining TransMolecular as a business development consultant, Radie held leadership roles at Prestwick Pharmaceuticals, Morphotek, and Vicuron Pharmaceuticals.

Rebecca is Xconomy's co-founder. Follow @

Trending on Xconomy